Jawad Ahmad1, Huiman X Barnhart2, Maurizio Bonacini3, Marwan Ghabril4, Paul H Hayashi5, Joseph A Odin6, Don C Rockey7, Simona Rossi8, Jose Serrano9, Hans L Tillmann10, David E Kleiner11. 1. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, United States. Electronic address: jawad.ahmad@mountsinai.org. 2. Duke Clinical Research Institute, Durham, NC, United States. 3. California Pacific Medical Center, San Francisco, CA, United States. 4. Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN, United States. 5. Food and Drug Administration, Silver Spring, MD, United States. 6. Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, United States. 7. Medical University of South Carolina, Charleston, SC, United States. 8. Einstein Medical Center, Philadelphia, PA, United States. 9. Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, United States. 10. Division of Gastroenterology, Hepatology and Nutrition, East Carolina University, Greenville, NC, United States. 11. Laboratory of Pathology, National Cancer Institute (NCI), Bethesda, MD, United States.
Abstract
BACKGROUND & AIMS: The utility of liver biopsy in diagnosing or staging idiosyncratic drug-induced liver injury (DILI) is unclear. The aim of this study was to determine whether liver histology impacted causality assessment in suspected DILI using a novel simulation model. METHODS: Fifty patients enrolled in the DILI Network (DILIN) who had liver biopsies performed within 60 days of DILI onset were randomly selected. All had standard DILIN consensus causality scoring using a 5-point scale (1=definite, 2=highly likely, 3=probable, 4=possible, 5=unlikely) based on 6-month post-injury data. Three experienced hepatologists independently performed a causality assessment using redacted case records, with the biopsy and selected post-biopsy laboratory data removed. The 3 hepatologists also reviewed the liver histology with a hepatopathologist and then repeated causality assessment for each case. RESULTS: Of the 50 cases, there were 42 high causality DILI cases (1, 2 or 3) and 8 low causality cases (4 and 5). The hepatologists judged that liver biopsy was indicated in 62% of patients; after histology review, biopsy was judged to have been helpful in 70% of patients. Histology review changed the causality score in 68% of patients, with an increase in DILI likelihood in 48% and a decrease in 20%. Biopsy results changed diagnostic certainty from less certain (3 or 4) to highly certain (1, 2 or 5) in 38% of patients. CONCLUSIONS: Liver histologic findings may help clarify the diagnosis of DILI. Histology appears to be particularly helpful in cholestatic or equivocal cases of DILI (possible or probable), shifting assessment toward a greater or lower certainty of a DILI diagnosis. LAY SUMMARY: The utility of liver biopsy in diagnosing or staging idiosyncratic drug-induced liver injury (DILI) is unclear. Herein, we show that, in patients with suspected DILI, a liver biopsy can help physicians diagnose DILI or other causes of liver injury with more certainty.
BACKGROUND & AIMS: The utility of liver biopsy in diagnosing or staging idiosyncratic drug-induced liver injury (DILI) is unclear. The aim of this study was to determine whether liver histology impacted causality assessment in suspected DILI using a novel simulation model. METHODS: Fifty patients enrolled in the DILI Network (DILIN) who had liver biopsies performed within 60 days of DILI onset were randomly selected. All had standard DILIN consensus causality scoring using a 5-point scale (1=definite, 2=highly likely, 3=probable, 4=possible, 5=unlikely) based on 6-month post-injury data. Three experienced hepatologists independently performed a causality assessment using redacted case records, with the biopsy and selected post-biopsy laboratory data removed. The 3 hepatologists also reviewed the liver histology with a hepatopathologist and then repeated causality assessment for each case. RESULTS: Of the 50 cases, there were 42 high causality DILI cases (1, 2 or 3) and 8 low causality cases (4 and 5). The hepatologists judged that liver biopsy was indicated in 62% of patients; after histology review, biopsy was judged to have been helpful in 70% of patients. Histology review changed the causality score in 68% of patients, with an increase in DILI likelihood in 48% and a decrease in 20%. Biopsy results changed diagnostic certainty from less certain (3 or 4) to highly certain (1, 2 or 5) in 38% of patients. CONCLUSIONS: Liver histologic findings may help clarify the diagnosis of DILI. Histology appears to be particularly helpful in cholestatic or equivocal cases of DILI (possible or probable), shifting assessment toward a greater or lower certainty of a DILI diagnosis. LAY SUMMARY: The utility of liver biopsy in diagnosing or staging idiosyncratic drug-induced liver injury (DILI) is unclear. Herein, we show that, in patients with suspected DILI, a liver biopsy can help physicians diagnose DILI or other causes of liver injury with more certainty.
Authors: Ayako Suzuki; Elizabeth M Brunt; David E Kleiner; Rosa Miquel; Thomas C Smyrk; Raul J Andrade; M Isabel Lucena; Agustin Castiella; Keith Lindor; Einar Björnsson Journal: Hepatology Date: 2011-08-08 Impact factor: 17.425
Authors: Herbert L Bonkovsky; David E Kleiner; Jiezhun Gu; Joseph A Odin; Mark W Russo; Victor M Navarro; Robert J Fontana; Marwan S Ghabril; Huiman Barnhart; Jay H Hoofnagle Journal: Hepatology Date: 2017-02-07 Impact factor: 17.425
Authors: Saleh A Alqahtani; David E Kleiner; Marwan Ghabril; Jiezhun Gu; Jay H Hoofnagle; Don C Rockey Journal: Clin Gastroenterol Hepatol Date: 2014-12-18 Impact factor: 11.382
Authors: Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi Journal: Hepatology Date: 2010-06 Impact factor: 17.425
Authors: Naga Chalasani; Herbert L Bonkovsky; Robert Fontana; William Lee; Andrew Stolz; Jayant Talwalkar; K Rajendar Reddy; Paul B Watkins; Victor Navarro; Huiman Barnhart; Jiezhun Gu; Jose Serrano Journal: Gastroenterology Date: 2015-03-06 Impact factor: 22.682
Authors: Robert J Fontana; Paul B Watkins; Herbert L Bonkovsky; Naga Chalasani; Timothy Davern; Jose Serrano; James Rochon Journal: Drug Saf Date: 2009 Impact factor: 5.606
Authors: Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins Journal: Am J Gastroenterol Date: 2015-09-08 Impact factor: 10.864
Authors: David E Kleiner; Naga P Chalasani; William M Lee; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Paul H Hayashi; Timothy J Davern; Victor Navarro; Rajender Reddy; Jayant A Talwalkar; Andrew Stolz; Jiezhun Gu; Huiman Barnhart; Jay H Hoofnagle Journal: Hepatology Date: 2013-12-18 Impact factor: 17.425
Authors: Paul H Hayashi; M Isabel Lucena; Robert J Fontana; Einar S Bjornsson; Guruprasad P Aithal; Huiman Barnhart; Andres Gonzalez-Jimenez; Qinghong Yang; Jiezhun Gu; Raul J Andrade; Jay H Hoofnagle Journal: Hepatology Date: 2022-03-22 Impact factor: 17.298